<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82319">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01920048</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN45979711</org_study_id>
    <secondary_id>ISRCTN45979711</secondary_id>
    <nct_id>NCT01920048</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure</brief_title>
  <acronym>REVIVED-BCIS2</acronym>
  <official_title>REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research (Health Technology Assessment Programme)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine (Clinical Trials Unit)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of York (Centre for Health Economics)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas' Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <authority>United Kingdom: National Institute for Health Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether percutaneous coronary intervention (angioplasty of the heart
      arteries) can improve survival and reduce hospitalization in patients with heart failure due
      to coronary disease, who have been treated with the best contemporary medical therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause death or Hospitalization for Heart Failure</measure>
    <time_frame>1 to 66 months (min follow-up duration: 24 months)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Scores and Functional Status</measure>
    <time_frame>6 months, 1 year, 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>6 months, 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death, myocardial infarction, cerebrovascular accident, major bleeding or unplanned revascularization</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>1 to 66 months (min follow-up duration: 24 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate Implantable Cardioverter Defibrillator Therapy</measure>
    <time_frame>6 months, 1 year, 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Myocardial Infarction</measure>
    <time_frame>1 to 66 months (min follow-up duration: 24 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned further revascularization</measure>
    <time_frame>1 to 66 months (min follow-up duration: 24 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-type Natriuretic Peptide level</measure>
    <time_frame>6 months, 1 year, 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>6 months, 1 year, 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Health Service Resource Use</measure>
    <time_frame>1 to 66 months (min follow-up duration: 24 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health Economic Analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Percutaneous Coronary Intervention and Optimal Medical Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention</intervention_name>
    <arm_group_label>Percutaneous Coronary Intervention and Optimal Medical Therapy</arm_group_label>
    <other_name>Coronary angioplasty/stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Therapy for Heart Failure</intervention_name>
    <description>The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines</description>
    <arm_group_label>Percutaneous Coronary Intervention and Optimal Medical Therapy</arm_group_label>
    <arm_group_label>Optimal Medical Therapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device Therapy for Heart Failure</intervention_name>
    <description>The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.</description>
    <arm_group_label>Percutaneous Coronary Intervention and Optimal Medical Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ALL of the following:

          1. Poor left ventricular function (EF≤30%)

          2. Extensive coronary disease (BCIS-1 Jeopardy Score ≥6)

          3. Viable myocardium in ≥30% of dysfunctional segments

        Main Exclusion Criteria:

          1. Significant angina (≥Canadian Cardiovascular Society class 3)

          2. Myocardial infarction &lt; 6 weeks previously

        Other Exclusions

          1. Decompensated heart failure requiring inotropic support, invasive or non-invasive
             ventilation or Intra-aortic Balloon Pump/left ventricular assist device therapy &lt;72
             hours prior to randomization

          2. Sustained Ventricular Tachycardia/Ventricular Fibrillation or appropriate Implantable
             Carioverter Defbrillator discharges &lt;72 hours prior to randomization

          3. More than mild aortic stenosis or mild aortic regurgitation on echocardiography

          4. Contra-indications to percutaenous cornoary intervention, including
             contra-indications to Aspirin or Clopidogrel or Heparin

          5. Age &lt;18 yrs

          6. Bleeding diathesis or Warfarin therapy with INR (International Normalized Ration)&gt;3.5

          7. Active internal bleeding (except menstruation)

          8. Platelet count &lt; 100,000 cells/mm3) at randomization

          9. Hemoglobin &lt; 90 g/L at randomization

         10. Estimated Glomerular Filtration Rate &lt; 25 ml/min, unless established on dialysis

         11. Women who are pregnant

         12. Previously enrolled in REVIVED-BCIS2 or current enrollment in other study that may
             affect REVIVED-BCIS2 outcome data

         13. Life expectancy &lt; 1 yr due to non-cardiac pathology
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Divaka Perera, MB BChir, MA, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Evans</last_name>
    <phone>+44 20 7927 2665</phone>
    <email>Richard.Evans@lshtm.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosemary Knight</last_name>
    <phone>+44 20 7927 2473</phone>
    <email>Rosemary.Knight@lshtm.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Clack</last_name>
      <phone>+44 20 7188 6271</phone>
      <email>Lucy.Clack@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sophie Jones</last_name>
      <phone>+44 20 7188 7188</phone>
      <email>Sophie.Jones@gstt.nhs.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 8, 2013</lastchanged_date>
  <firstreceived_date>August 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King's College London</investigator_affiliation>
    <investigator_full_name>Divaka Perera</investigator_full_name>
    <investigator_title>Consultant Cardiologist and Reader in Interventional Cardiology</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Ventricular Dysfunction</keyword>
  <keyword>Ischemic Cardiomyopathy</keyword>
  <keyword>Ischemic Heart Disease</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Randomized Control Trial</keyword>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
